دورية أكاديمية
أعرض في EDS

Impact of Combined Subthalamic Nucleus and Substantia Nigra Stimulation on Neuropsychiatric Symptoms in Parkinson's Disease Patients.

التفاصيل البيبلوغرافية
العنوان: Impact of Combined Subthalamic Nucleus and Substantia Nigra Stimulation on Neuropsychiatric Symptoms in Parkinson's Disease Patients.
المؤلفون: Hidding U; Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Gulberti A; Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Department of Neurophysiology and Pathophysiology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Horn A; Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Buhmann C; Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Hamel W; Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Koeppen JA; Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Westphal M; Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Engel AK; Department of Neurophysiology and Pathophysiology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Gerloff C; Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Weiss D; Department for Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany., Moll CK; Department of Neurophysiology and Pathophysiology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Pötter-Nerger M; Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
المصدر: Parkinson's disease [Parkinsons Dis] 2017; Vol. 2017, pp. 7306192. Date of Electronic Publication: 2017 Jan 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Country of Publication: United States NLM ID: 101539877 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2090-8083 (Print) Linking ISSN: 20420080 NLM ISO Abbreviation: Parkinsons Dis Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2011- : New York : Hindawi
Original Publication: [London] : SAGE-Hindawi Access to Research
مستخلص: The goal of the study was to compare the tolerability and the effects of conventional subthalamic nucleus (STN) and combined subthalamic nucleus and substantia nigra (STN+SNr) high-frequency stimulation in regard to neuropsychiatric symptoms in Parkinson's disease patients. In this single center, randomized, double-blind, cross-over clinical trial, twelve patients with advanced Parkinson's disease (1 female; age: 61.3 ± 7.3 years; disease duration: 12.3 ± 5.4 years; Hoehn and Yahr stage: 2.2 ± 0.39) were included. Apathy, fatigue, depression, and impulse control disorder were assessed using a comprehensive set of standardized rating scales and questionnaires such as the Lille Apathy Rating Scale (LARS), Modified Fatigue Impact Scale (MFIS), Becks Depression Inventory (BDI-I), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS), and Parkinson's Disease Questionnaire (PDQ-39). Three patients that were initially assigned to the STN+SNr stimulation mode withdrew from the study within the first week due to discomfort. Statistical comparison of data retrieved from patients who completed the study revealed no significant differences between both stimulation conditions in terms of mean scores of scales measuring apathy, fatigue, depression, impulse control disorder, and quality of life. Individual cases showed an improvement of apathy under combined STN+SNr stimulation. In general, combined STN+SNr stimulation seems to be safe in terms of neuropsychiatric side effects, although careful patient selection and monitoring in the short-term period after changing stimulation settings are recommended.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interests. All authors declare no relevant conflict of interests. Some of the authors (U. Hidding, A. Gulberti, A. Horn, C. Buhmann, W. Hamel, C. K. E. Moll, and M. Pötter-Nerger) have occasionally been reimbursed for travel expenses from Medtronic Inc. C. Buhmann served on the scientific advisory board for GSK and UCB Pharma and received honoraria for lectures from GSK, Medtronic, Orion Pharma, and UCB. M. Pötter-Nerger served in advisory boards for Boston scientific, St. Jude, and AbbVie.
References: J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):701-7. (PMID: 12023409)
Neurology. 1967 May;17(5):427-42. (PMID: 6067254)
Neurology. 2008 Apr 15;70(16 Pt 2):1445-51. (PMID: 18413569)
Brain Cogn. 2000 Apr;42(3):324-47. (PMID: 10753483)
Mov Disord. 2008 May 15;23(7):1043-6. (PMID: 18381646)
Mult Scler. 2002 Dec;8(6):523-6. (PMID: 12474995)
J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):774-83. (PMID: 23064099)
Prog Brain Res. 1990;85:119-46. (PMID: 2094891)
J Neurol Neurosurg Psychiatry. 2006 May;77(5):579-84. (PMID: 16614016)
N Engl J Med. 2010 Jun 3;362(22):2077-91. (PMID: 20519680)
Mov Disord. 2015 Feb;30(2):238-44. (PMID: 25545969)
Physiol Rev. 1983 Jul;63(3):844-914. (PMID: 6308694)
Parkinsons Dis. 2012;2012:793076. (PMID: 22203919)
Mov Disord. 2014 Jun;29(7):897-903. (PMID: 24817690)
Mov Disord. 2011 May;26(6):1022-31. (PMID: 21626547)
Eur J Neurol. 2015 Feb;22(2):253-60. (PMID: 24848193)
Parkinsonism Relat Disord. 2013 Mar;19(3):335-8. (PMID: 23246138)
Mov Disord. 2000 Nov;15(6):1221-4. (PMID: 11104209)
Front Behav Neurosci. 2016 May 03;10:85. (PMID: 27199693)
Psychol Sci. 2009 Nov;20(11):1322-31. (PMID: 19883494)
Clin Infect Dis. 1994 Jan;18 Suppl 1:S79-83. (PMID: 8148458)
Arch Neurol. 2011 Feb;68(2):165. (PMID: 20937936)
Ther Adv Neurol Disord. 2009 Jul;2(4):205-14. (PMID: 21179529)
J Neurol Sci. 2015 Sep 15;356(1-2):32-44. (PMID: 26123201)
Prog Brain Res. 2000;126:165-82. (PMID: 11105646)
N Engl J Med. 1999 May 13;340(19):1476-80. (PMID: 10320386)
J Neurol. 2011 Jun;258(6):1183-5. (PMID: 21287187)
Lancet Neurol. 2010 Jun;9(6):581-91. (PMID: 20434403)
Neuropsychol Rev. 2015 Dec;25(4):398-410. (PMID: 26577509)
J Neurosci. 2014 Apr 30;34(18):6273-85. (PMID: 24790198)
Mov Disord. 2015 Apr 15;30(5):671-9. (PMID: 25600482)
Arch Gen Psychiatry. 1961 Jun;4:561-71. (PMID: 13688369)
N Engl J Med. 2006 Aug 31;355(9):896-908. (PMID: 16943402)
J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):607-14. (PMID: 21047882)
Lancet Neurol. 2015 May;14(5):518-31. (PMID: 25895932)
Acta Neurochir Suppl. 2013;117:19-25. (PMID: 23652652)
J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1036-46. (PMID: 12876231)
Brain. 2000 Sep;123 ( Pt 9):1767-83. (PMID: 10960043)
Stereotact Funct Neurosurg. 2015;93(4):265-70. (PMID: 26066569)
J Neurol. 2002 Oct;249 Suppl 3:III/1-5. (PMID: 12528692)
Age Ageing. 1997 Sep;26(5):353-7. (PMID: 9351479)
J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668-74. (PMID: 24218528)
Brain. 2016 Sep;139(Pt 9):2486-502. (PMID: 27538418)
Neurology. 2009 Nov 17;73(20):1699-704. (PMID: 19917994)
Mov Disord. 2008 Jan;23(1):42-6. (PMID: 17973326)
Prog Brain Res. 1996;107:379-402. (PMID: 8782532)
J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):311-8. (PMID: 25934016)
J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):675-83. (PMID: 24227759)
Mov Disord. 2002;17 Suppl 3:S22-7. (PMID: 11948752)
Sleep Med. 2005 Jun;6 Suppl 1:S3-7. (PMID: 16140243)
Mov Disord. 2012 Feb;27(2):242-7. (PMID: 22134954)
Mov Disord. 2016 Aug;31(8):1103-13. (PMID: 27041545)
J Neuropsychiatry Clin Neurosci. 2012 Winter;24(1):102-10. (PMID: 22450620)
Mov Disord. 2015 Feb;30(2):229-37. (PMID: 25449044)
Eur J Neurosci. 2005 Nov;22(9):2283-94. (PMID: 16262666)
Curr Opin Neurol. 2015 Aug;28(4):344-50. (PMID: 26110801)
Mov Disord. 2010 Nov 15;25(15):2649-53. (PMID: 21069833)
Mov Disord. 2014 Dec;29(14):1796-801. (PMID: 25370724)
Handb Clin Neurol. 2013;116:97-105. (PMID: 24112888)
Trials. 2011 Oct 11;12:222. (PMID: 21989388)
J Neurol. 2014 May;261(5):936-42. (PMID: 24609972)
Eur J Neurol. 2009 Apr;16(4):493-7. (PMID: 19236471)
Front Syst Neurosci. 2014 Feb 11;8:15. (PMID: 24574981)
Lancet Neurol. 2012 Feb;11(2):140-9. (PMID: 22239915)
Neurology. 2004 Oct 12;63(7):1234-9. (PMID: 15477544)
J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1363-6. (PMID: 17110749)
Eur J Neurosci. 2001 Dec;14(11):1833-42. (PMID: 11860479)
J Parkinsons Dis. 2015;5(3):625-36. (PMID: 25870025)
Neurology. 2009 Nov 24;73(21):1746-51. (PMID: 19933975)
Brain. 2013 Jul;136(Pt 7):2098-108. (PMID: 23757762)
Mov Disord. 2010 Oct 30;25(14):2318-25. (PMID: 20669264)
J Neurol Sci. 2011 Nov 15;310(1-2):216-9. (PMID: 21689829)
J Neurol Neurosurg Psychiatry. 2007 May;78(5):517-9. (PMID: 17210626)
J Psychosom Res. 2011 Jan;70(1):73-97. (PMID: 21193104)
تواريخ الأحداث: Date Created: 20170302 Latest Revision: 20200930
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5299199
DOI: 10.1155/2017/7306192
PMID: 28246572
قاعدة البيانات: MEDLINE
الوصف
تدمد:2090-8083
DOI:10.1155/2017/7306192